Biblio
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy. Cancer. 2023.
Multiple Myeloma in 2023 Ways: From Trials to Real Life. Curr Oncol. 2023;30(11):9710-9733.
. IGFBP-6/sonic hedgehog/TLR4 signalling axis drives bone marrow fibrotic transformation in primary myelofibrosis. Aging (Albany NY). 2021;13(undefined).
RISK FACTORS FOR PROGRESSION TO BLAST PHASE AND OUTCOME IN 589 PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB: REAL WORLD DATA. Hematol Oncol. 2020.
Second primary malignancy in myelofibrosis patients treated with ruxolitinib. Br J Haematol. 2020.